Thaher Pelaseyed

Co-founder & Chief Executive Officer MucoLife Therapeutics

Seminars

Tuesday 15th September 2026
Unlocking the Power of Advanced Imaging Technologies from MRI to MicroCT & Evolving AI & ML to Drug Development From POC to Target Engagement, Diagnosis, & Disease Progression in COPD
1:00 pm

This hands-on workshop will explore how advanced imaging technologies combined with artificial intelligence are revolutionizing respiratory research. Attendees will gain practical insights into leveraging high-resolution imaging, machine learning, and novel diagnostic tools to better understand disease progression, identify patient subtypes, and accelerate drug development. The session will focus on actionable strategies to integrate imaging and AI into translational research and early-phase clinical programs.

Workshop Highlights

  • Explore cutting-edge imaging technologies to assess structural and functional lung changes, providing more precise measures of disease progression and treatment response including how imaging modalities can compliment each other
  • Learn how AI enhances imaging interpretation, enabling rapid, reproducible analysis of complex datasets and uncovering novel biomarkers previously inaccessible through manual review
  • Understand practical applications for early detection, including oscillometry and imaging-derived endpoints, to support earlier intervention and improved patient stratification
  • Evaluate integration of imaging with molecular and clinical data, enabling a holistic view of disease biology and more accurate identification of patient subtypes
  • Gain insights into translational and drug development potential, including how AI-driven imaging can accelerate early proof-of-concept studies and inform next-generation endpoints, while recognizing technical and regulatory considerations
Tuesday 15th September 2026
Targeting Muco-Obstructive Lesions to Redefine COPD Treatment
3:45 pm
  • Mucus plugs represent the last untargeted cause of airway obstruction in COPD, persisting even in patients escalated to triple therapy or biologics
  • MLT-001 by MucoLife Therapeutics is a first-in-class inhaled mucus modulator with a novel mechanism of action that directly dissolves mucus plugs with demonstrated 90% preclinical efficacy and a wide therapeutic index
  • The talk will highlight the addressable COPD subgroup and how MLT-001 is positioned as a once-daily inhaled add-on maintenance therapy within the existing treatment paradigm. Additionally, the presentation will explore the broader platform potential of this mechanism across other muco-obstructive diseases, including non-CF bronchiectasis, asthma
Thaher Pelaseyed